Trial reportSignal transduction and targeted therapy2021
Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.
Open access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Beneficial and Harmful Effects of Monoclonal Antibodies for the Treatment and Prophylaxis of COVID-19: Systematic Review and Meta-Analysis.The American journal of medicine · 2022Pooled it
- Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.British journal of clinical pharmacology · 2026Trial
- Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial.Signal transduction and targeted therapy · 2025Trial
- Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer.BMC cancer · 2024Trial
- Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial.Signal transduction and targeted therapy · 2023Trial
- Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial.Antimicrobial agents and chemotherapy · 2022Trial
- Malaria Prevention: Progress to Date.Drugs · 2026Review
- Fc engineering of a fully humanized anti-CD147 monoclonal antibody enhances ADCC against T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.Scientific reports · 2026Article
- Inducible CD147 up-regulation boosts extended SARS-CoV-2 infection triggering severe COVID-19 independent of ACE2.Signal transduction and targeted therapy · 2026Article
- CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025Review
- SARS-CoV-2 uptake and inflammatory response in senescent endothelial cells are regulated by the BSG/VEGFR2 pathway.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Defining diverse spike-receptor interactions involved in SARS-CoV-2 entry: Mechanisms and therapeutic opportunities.Virology · 2025Review
- CD147-high classical monocytes: a cellular biomarker for COVID-19 disease severity and treatment response.Inflammation and regeneration · 2025Article
- Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.Infectious disease reports · 2025Article
- Cyclophilin-CD147 interaction enables SARS-CoV-2 infection of human monocytes and their activation via Toll-like receptors 7 and 8.Frontiers in immunology · 2025Article
- Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes.Emerging microbes & infections · 2024Article
- Lactylation: A Novel Post-Translational Modification with Clinical Implications in CNS Diseases.Biomolecules · 2024Review
- Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval.Journal of Korean medical science · 2024Review
- Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
58 authors at 2 institutions in 1 country.
Huijie Bian *National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China. hjbian@fmmu.edu.cn.ORCID 0000-0003-4690-4622
Zhao-Hui Zheng *Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Ding Wei *National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Aidong Wen *Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Zheng Zhang *National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Jian-Qi Lian *Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Wen-Zhen Kang *Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Chun-Qiu Hao *Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Jing Wang *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Rong-Hua XieDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Ke DongDepartment of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Jie-Lai XiaCollege of Military Preventive Medicine, Fourth Military Medical University, Xi'an, China.
Jin-Lin MiaoNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Wen KangCenter for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Guoquan LiDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Di ZhangDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Mingru ZhangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Xiu-Xuan SunNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Likun DingDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Kui ZhangDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Junfeng JiaDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Jin DingDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Zhiqin LiDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Yanyan JiaDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Lin-Na LiuDepartment of Pharmaceutics, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Zhe ZhangDepartment of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Zhao-Wei GaoDepartment of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Hong DuCenter for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Na YaoCenter for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Qing WangDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Ke WangNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Jie-Jie GengNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Bin WangNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Ting GuoNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Ruo ChenNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Yu-Meng ZhuNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Li-Juan WangNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Qian HeNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Rui-Rui YaoNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Ying ShiNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Xiang-Min YangNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Jian-Sheng ZhouNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Yi-Nan MaNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Ya-Tao WangNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Xue LiangNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Fei HuoNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Zhe WangDepartment of Pathology, Fourth Military Medical University, Xi'an, China.
Yang ZhangNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Xu YangNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Ye ZhangCenter for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Lu-Hua GaoCenter for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Ling WangCollege of Military Preventive Medicine, Fourth Military Medical University, Xi'an, China.
Xiao-Chun ChenJiangsu Pacific Meinuoke Biopharmaceutical Co. Ltd, Changzhou, China.
Hao TangJiangsu Pacific Meinuoke Biopharmaceutical Co. Ltd, Changzhou, China.
Shuang-Shuang LiuJiangsu Pacific Meinuoke Biopharmaceutical Co. Ltd, Changzhou, China.
Qing-Yi WangDepartment of Foreign Languages, Fourth Military Medical University, Xi'an, China.
Zhi-Nan ChenNational Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China. znchen@fmmu.edu.cn.
Ping ZhuDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. zhuping@fmmu.edu.cn.
Air Force Medical University · CNXijing Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Blocking CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 replication. Meplazumab is a humanized anti-CD147 IgG
Indexed as
Antibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentAdolescentAdultCOVID-19Double-Blind MethodFemaleHumansLungMaleMiddle AgedSARS-CoV-2Antibodies, Monoclonal, Humanizedmeplazumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.